We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+31.67%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.09B
AUM Growth
+$628M
Cap. Flow
+$36.4M
Cap. Flow %
1.18%
Top 10 Hldgs %
71.33%
Holding
29
New
3
Increased
10
Reduced
10
Closed
1

Top Buys

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$54.1M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$35M
3
GILD icon
Gilead Sciences
GILD
+$15.5M
4
CEMP
Cempra, Inc.
CEMP
+$11.6M
5
PBYI icon
Puma Biotechnology
PBYI
+$9.98M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$32.6M
2
CELG
Celgene Corp
CELG
+$18.5M
3
INCY icon
Incyte
INCY
+$16.3M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.8M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 81.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INVA icon
26
Innoviva
INVA
$1.48B
$14.8M 0.48%
1,043,244
+300,000
+40% +$4.51M
ACHN
27
DELISTED
Achillion Pharmaceuticals
ACHN
$13.2M 0.43%
1,079,340
-200,000
-16% -$2.44M
ECYT
28
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-683,522
Closed -$4.16M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q4 2014 Portfolio in Review

As of Q4 2014, BB Biotech held 29 positions worth $3.09B, up 26% from $2.46B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

BB Biotech's Q4 2014 filing shows 3 new, 10 increased, 10 reduced and 1 closed positions. Its largest new stake was PTC Therapeutics: 1,227,912 shares worth $63.6M. The largest sale was Ionis Pharmaceuticals, an estimated $32.6M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier.

  • BB Biotech's largest Q4 2014 buy was PTC Therapeutics: 1,227,912 shares worth $63.6M.
  • BB Biotech added most to Gilead Sciences in Q4 2014, an estimated $15.5M increase.
  • BB Biotech's biggest Q4 2014 reduction was Ionis Pharmaceuticals, cutting an estimated $32.6M.
  • BB Biotech fully exited Endocyte, Inc. Common Stock in Q4 2014, selling an estimated $4.16M.
  • BB Biotech's ten largest holdings make up 71% of its $3.09B portfolio in Q4 2014.
  • BB Biotech opened 3 new positions and closed 1 in Q4 2014.
  • BB Biotech's portfolio value rose 26% quarter-over-quarter to $3.09B.

Based on BB Biotech's 13F filing for Q4 2014, filed 12 Feb 2015.